Track topics on Twitter Track topics that are important to you
Sanofi exuded renewed confidence in its updated forecast for 2017 on the back of a Q2 report which illustrated strong growth for the French company, particularly in its vaccines and consumer health divisions, as well as Genzyme, its speciality care global business.
Original Article: Strong Q2 growth for Sanofi raises 2017 sales outlookNEXT ARTICLE
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...